Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05638763

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Conditions: Chronic Myeloid Leukemia, Chronic Phase

Sex: All

Ages: 18 Years – N/A

Phase: PHASE2

Enrollment: 15

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Location: Mexico

Summary

This phase 2 single-arm study aims to demonstrate the efficacy of strong cytochrome inhibition with ketoconazole to reduce dasatinib dosage for adults with chronic myelogenous leukemia. Researchers will describe response rates and adverse events.

Eligibility Criteria

Inclusion Criteria:Age >18 yearsChronic myeloid leukemia in chronic phase according to the World Health Organization 2016Eastern Cooperative Oncology Group (ECOG) 0-2Exclusion Criteria:Chronic heart disease (NYHA III-IV)Bleeding disorders not attributed to the hematological malignancyPregnancyLactationChronic myeloid leukemia in blast phaseOrganic dysfunction (Marshall score ≥2)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05638763). StuddyBuddy aggregates publicly available trial information.